NODX-010 / Nodus Oncology, Basilea - LARVOL DELTA

Nodus Oncology announces acquisition of Basilea Pharmaceutica’s PARG inhibitor programme (GlobeNewswire) - "Nodus Oncology...is pleased to announce the completion of an Asset Purchase Agreement (APA) for Basilea Pharmaceutica’s ...novel poly(ADP-ribose) glycohydrolase (PARG) inhibitor discovery programme. Nodus secures worldwide development and commercialization rights to Basilea’s PARG inhibitor (PARGi) programme – currently at the discovery stage - which has the potential to be a best-in-class treatment for molecularly defined patient sub-groups...Under the terms of the agreement, Basilea receives an upfront and near-term research milestone payment of CHF 1.0 million and is eligible for further payments, upon the achievement of predefined development, regulatory and sales milestones based on entry to the clinic and regulatory approval in the U.S. and Europe."

Commercial • Oncology